Nassau, NY, United States of America

Matthew Ernst Voss




Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 114(Granted Patents)


Location History:

  • Lincoln University, PA (US) (1993 - 2005)
  • Lincoln Univ., PA (US) (2006)
  • Nassau, NY (US) (2007 - 2014)
  • Singapore, SG (2014 - 2017)
  • Ville de West, SG (2015 - 2017)

Company Filing History:


Years Active: 1993-2017

Loading Chart...
Loading Chart...
Loading Chart...
30 patents (USPTO):

Title: Unveiling the Innovations of Inventor Matthew Ernst Voss

Introduction:

Matthew Ernst Voss, a prolific inventor hailing from Nassau, NY, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 30 patents. Voss is renowned for his groundbreaking work in developing compounds that serve as inhibitors of the HDM2 protein, offering potential avenues for treating cancer.

Latest Patents:

1. 2,6,7 substituted purines as HDM2 inhibitors: Voss's patent introduces 2,6,7 substituted purines as inhibitors of the HDM2 protein, with promising implications for cancer treatment. The patent also encompasses pharmaceutical compositions utilizing these compounds.

2. Substituted pyrrolopyrimidines as HDM2 inhibitors: Another pioneering patent by Voss unveils substituted pyrrolopyrimidines as inhibitors of the HDM2 protein. These compounds offer valuable prospects for cancer therapy and are featured in pharmaceutical compositions.

Career Highlights:

Matthew Ernst Voss has garnered experience and expertise through his tenure at esteemed pharmaceutical companies. Noteworthy chapters of his career include contributions made at Merck Sharp & Dohme Corporation and The Dupont Merck Pharmaceutical Company. His innovative spirit and dedication have propelled advancements in the pharmaceutical industry.

Collaborations:

Throughout his career, Voss has collaborated closely with accomplished professionals in the field. Notable among his coworkers are Stephane L Bogen and Jingwu Duan, individuals who have shared in Voss's journey of innovation and discovery. Their collective efforts have led to transformative developments in pharmaceutical research.

Conclusion:

In conclusion, Matthew Ernst Voss stands as a pioneering figure in the realm of pharmaceutical innovation, with a rich tapestry of patents and contributions that underscore his commitment to advancing cancer treatment. Through collaborations and career milestones, Voss has left an indelible mark on the field, shaping the landscape of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…